Quipt Home Medical says its effectively managing industry-wide pressures 

CINCINNATI – Quipt Home Medical has reported revenue of $68.3 million for the fourth quarter of 2025, an 11% increase year over year. It has reported revenue of $245.5 million for fiscal year 2025, a slight decrease. 

Net income for Q4 was a loss of $3.6 million compared to a loss of $2.9 million for the same period last year. Net income for FY25 was a loss of $10.7 million compared to a loss of $6.8 million last year. 

Chairman and CEO Greg Crawford highlighted the company’s sequential improvements, including a 5% increase in organic revenue from the third quarter to fourth quarter of 2025. 

“In the fourth quarter, we delivered strong sequential organic growth, effectively managed industry-wide pressures, and continued scaling our platform,” he said. 

Other financial highlights: 

• Adjusted EBITDA for Q4 2025 was $14.9 million (21.8% as a percentage of revenues) compared to $13.4 million (21.9% as a percentage of revenues) for Q4 2024, representing an 11% increase. 
• Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% as a percentage of revenue), compared to adjusted EBITDA for fiscal year 2024 of $57.7 million (23.5% as a percentage of revenue), representing a 3% decrease. 

Operational highlights: 

• Quipt Home Medical's customer base increased 10% year over year to 346,000 unique patients served in fiscal year 2025 compared to 314,000 unique patients in fiscal year 2024. 
• Compared to 854,000 unique setups/deliveries in fiscal year 2024, the company completed 917,000 unique set-ups/deliveries in fiscal year 2025, a 7% increase. This includes 486,000 respiratory resupply setups/deliveries for the year ended Sept. 30, 2025, compared to 480,000 for the year ended Sept. 30, 2024, relatively flat. The company credits its continued use of technology and centralized intake processes.